A Novel Insulin Sensitizer Drug Candidate—BGP-15—Can Prevent Metabolic Side Effects of Atypical Antipsychotics

Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for Atrial Fibrillation

(2011) Deli Zhang et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Membrane-Lipid Therapy in Operation: The HSP Co-Inducer BGP-15 Activates Stress Signal Transduction Pathways by Remodeling Plasma Membrane Rafts

(2011) Imre Gombos et al.   PLoS One

Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders

(2010) B. Literáti-Nagy et al.   BRAIN RESEARCH BULLETIN

A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia

(2009) D. C. Henderson et al.   ACTA PSYCHIATRICA SCANDINAVICA

Improvement of Insulin Sensitivity by a Novel Drug, BGP-15, in Insulin-resistant Patients: A Proof of Concept Randomized Double-blind Clinical Trial

(2009) B. Literáti-Nagy et al.   HORMONE AND METABOLIC RESEARCH

Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial

(2009) T. Baptista et al.   PHARMACOPSYCHIATRY

Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain

(2008) Ren-Rong Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

HSP72 protects against obesity-induced insulin resistance

(2008) J. Chung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA